JP2018502572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502572A5 JP2018502572A5 JP2017534345A JP2017534345A JP2018502572A5 JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5 JP 2017534345 A JP2017534345 A JP 2017534345A JP 2017534345 A JP2017534345 A JP 2017534345A JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- bispecific antibody
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562099236P | 2015-01-02 | 2015-01-02 | |
| US62/099,236 | 2015-01-02 | ||
| US201562200363P | 2015-08-03 | 2015-08-03 | |
| US62/200,363 | 2015-08-03 | ||
| US201562261609P | 2015-12-01 | 2015-12-01 | |
| US62/261,609 | 2015-12-01 | ||
| PCT/US2015/068238 WO2016109774A1 (en) | 2015-01-02 | 2015-12-31 | Bispecific antibodies against plasma kallikrein and factor xii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Division JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502572A JP2018502572A (ja) | 2018-02-01 |
| JP2018502572A5 true JP2018502572A5 (enExample) | 2019-02-14 |
| JP6744313B2 JP6744313B2 (ja) | 2020-08-26 |
Family
ID=56285069
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534345A Active JP6744313B2 (ja) | 2015-01-02 | 2015-12-31 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11390687B2 (enExample) |
| EP (1) | EP3240570B1 (enExample) |
| JP (4) | JP6744313B2 (enExample) |
| KR (2) | KR20240091031A (enExample) |
| CN (2) | CN107405399B (enExample) |
| AU (2) | AU2015373910B2 (enExample) |
| CA (1) | CA2972800A1 (enExample) |
| CO (1) | CO2017007123A2 (enExample) |
| EA (1) | EA201791527A1 (enExample) |
| IL (2) | IL298086B2 (enExample) |
| MX (2) | MX2017008541A (enExample) |
| NZ (1) | NZ771568A (enExample) |
| WO (1) | WO2016109774A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972800A1 (en) | 2015-01-02 | 2016-07-07 | Dyax Corp. | Bispecific antibodies against plasma kallikrein and factor xii |
| US10913802B2 (en) * | 2015-07-21 | 2021-02-09 | Dyax Corp. | Monoclonal antibody inhibitor of factor XIIA |
| JP7319916B2 (ja) | 2016-09-16 | 2023-08-02 | 武田薬品工業株式会社 | 遺伝性血管性浮腫のｒｎａバイオマーカー |
| KR20190118172A (ko) | 2017-02-08 | 2019-10-17 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CN111065649A (zh) * | 2017-08-16 | 2020-04-24 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和egfr、hla-e、ccr4或pd-l1的蛋白质 |
| CA3079568A1 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| CN119291194A (zh) * | 2018-01-12 | 2025-01-10 | 建新公司 | 用于定量多肽的方法 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| WO2019157366A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008684A (es) * | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| BR112020024992A2 (pt) * | 2018-06-08 | 2021-03-23 | Modalis Therapeutics Corporation | proteína cas9 modificada e uso da mesma |
| BR112021000383A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1 |
| MX2021001527A (es) * | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| BR112021002278A2 (pt) * | 2018-08-08 | 2021-07-20 | Dragonfly Therapeutics, Inc. | proteínas que ligam nkg2d, cd16 e um antígeno associado a tumor |
| CA3114803A1 (en) * | 2018-10-24 | 2020-04-30 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| PH12022550195A1 (en) | 2019-07-26 | 2022-11-21 | Janssen Biotech Inc | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| US20230390418A1 (en) * | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| WO2022156799A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| WO2022156798A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN115925967A (zh) * | 2021-04-22 | 2023-04-07 | 广东菲鹏制药股份有限公司 | 双特异性多功能融合多肽 |
| WO2024238407A2 (en) * | 2023-05-12 | 2024-11-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of treating dilated cardiomyopathy and heart failure |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
| US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5759573A (en) | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
| AU686277B2 (en) | 1993-11-16 | 1998-02-05 | Pacira Pharmaceuticals, Inc. | Vesicles with controlled release of actives |
| ES2297831T3 (es) | 1994-05-09 | 2008-05-01 | Oxford Biomedica (Uk) Limited | Vectores retroviricos que presentan una tasa de recombinacion reducida. |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| GB9609262D0 (en) | 1996-05-02 | 1996-07-03 | Isis Innovation | Peptide library and method |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CN101260156A (zh) * | 2002-06-28 | 2008-09-10 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| US8119137B2 (en) | 2004-12-23 | 2012-02-21 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII |
| GB0500487D0 (en) | 2005-01-11 | 2005-02-16 | Axis Shield Diagnostics Ltd | Forms of factor XIIa |
| US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| TWI496582B (zh) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| US8388959B2 (en) | 2008-12-18 | 2013-03-05 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| KR101398363B1 (ko) | 2010-11-17 | 2014-05-22 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| KR102107695B1 (ko) * | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| PT2734552T (pt) | 2011-07-22 | 2025-01-29 | Csl Behring Gmbh | Anticorpos monoclonais inibidores do fator xii/xiia e suas utilizações |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| JP5653860B2 (ja) | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
| EP3617313A1 (en) * | 2011-10-05 | 2020-03-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain |
| PL2794905T3 (pl) * | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| ES2698950T3 (es) | 2012-05-10 | 2019-02-06 | Bayer Pharma AG | Anticuerpos capaces de unirse al Factor XI de coagulación y/o a su forma activada, Factor XIa, y usos de los mismos |
| US20140038204A1 (en) * | 2012-07-31 | 2014-02-06 | Baxter Healthcare S.A. | Selective measurement of active human protease coagulation factors |
| US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
| LT2946206T (lt) | 2013-01-20 | 2019-04-25 | Dyax Corp. | Pkal sąlygotų sutrikimų vertinimas, tyrimas ir gydymas |
| AU2014240045A1 (en) * | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| PL3013366T3 (pl) * | 2013-06-28 | 2022-01-17 | Csl Behring Gmbh | Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1 |
| EP3024851B1 (en) | 2013-07-25 | 2018-05-09 | CytomX Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| CA2972800A1 (en) | 2015-01-02 | 2016-07-07 | Dyax Corp. | Bispecific antibodies against plasma kallikrein and factor xii |
| US10913802B2 (en) | 2015-07-21 | 2021-02-09 | Dyax Corp. | Monoclonal antibody inhibitor of factor XIIA |
| EP3263803B1 (en) | 2016-06-30 | 2019-08-14 | ABB Schweiz AG | Substation |
-
2015
- 2015-12-31 CA CA2972800A patent/CA2972800A1/en active Pending
- 2015-12-31 MX MX2017008541A patent/MX2017008541A/es unknown
- 2015-12-31 AU AU2015373910A patent/AU2015373910B2/en active Active
- 2015-12-31 IL IL298086A patent/IL298086B2/en unknown
- 2015-12-31 CN CN201580075633.1A patent/CN107405399B/zh active Active
- 2015-12-31 KR KR1020247017566A patent/KR20240091031A/ko active Pending
- 2015-12-31 KR KR1020177021610A patent/KR102670705B1/ko active Active
- 2015-12-31 JP JP2017534345A patent/JP6744313B2/ja active Active
- 2015-12-31 IL IL253180A patent/IL253180B2/en unknown
- 2015-12-31 EP EP15876336.7A patent/EP3240570B1/en active Active
- 2015-12-31 EA EA201791527A patent/EA201791527A1/ru unknown
- 2015-12-31 WO PCT/US2015/068238 patent/WO2016109774A1/en not_active Ceased
- 2015-12-31 CN CN202210054884.3A patent/CN114316061B/zh active Active
- 2015-12-31 NZ NZ771568A patent/NZ771568A/en unknown
- 2015-12-31 US US15/541,066 patent/US11390687B2/en active Active
-
2017
- 2017-06-26 MX MX2024000317A patent/MX2024000317A/es unknown
- 2017-07-17 CO CONC2017/0007123A patent/CO2017007123A2/es unknown
-
2020
- 2020-07-30 JP JP2020128994A patent/JP7003347B2/ja active Active
-
2021
- 2021-09-16 JP JP2021150755A patent/JP7241827B2/ja active Active
-
2022
- 2022-02-17 AU AU2022201076A patent/AU2022201076B2/en active Active
- 2022-06-13 US US17/838,769 patent/US12240918B2/en active Active
-
2023
- 2023-03-07 JP JP2023035060A patent/JP7635285B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502572A5 (enExample) | ||
| JP2020186248A5 (enExample) | ||
| CN106459220B (zh) | 适用于高通量筛选的新的双特异性形式 | |
| US11286312B2 (en) | Multispecific antibodies | |
| JP2016533174A5 (enExample) | ||
| KR102282691B1 (ko) | 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법 | |
| JP7203800B2 (ja) | ヌクレオチド・ライブラリー | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2017512063A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2017509335A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2014521313A5 (enExample) | ||
| KR20190111946A (ko) | 1가 항-프로페르딘 항체 및 항체 단편 | |
| JP2019506839A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| CN111526887A (zh) | 用于使血清中的蛋白质半衰期增加的组合物和方法 | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| JP6247646B2 (ja) | ヒト化抗ｈｍｇｂ１抗体もしくはその抗原結合性断片 | |
| Henry et al. | A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders | |
| Aoki et al. | Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor | |
| CN107073093A (zh) | 亲和蛋白及其用途 | |
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides |